Podcasts about ozempic

Dave Rubin of "The Rubin Report" talks to DeVory Darkins and "We the People's" Gates Garcia about Donald Trump's risky claim of the Iran War already being over; Gavin Newsom filing a civil rights complaint against Dr. Mehmet Oz for his exposure of hospice fraud in the Armenian community in California; Adam Carolla finally losing his cool over how awful Gavin Newsom is; Tim Walz telling Kara Swisher why Kristi Noem must be put on trial for the crimes committed by ICE once Democrats get back in power; Joe Borelli humiliating MeidasTouch's Adam Mockler on CNN for trying to claim that Pete Hegseth and Donald Trump have no strategy or plan for the Iran War; "This Week on the Internet" featuring new made of cardboard Iran supreme leader Mojtaba Khamenei, Zohran Mamdani trying to ignore his wife, Rama Duwaji's, pro-October 7th Hamas tweets, Margot Robbie being eaten alive by Ozempic; Timothée Chalamet enraging the ballet community for pointing out the obvious; Donald Trump trying to decide between Marco Rubio and JD Vance; and much more. WATCH the MEMBER-EXCLUSIVE segment of the show here: https://rubinreport.locals.com/ Check out the NEW RUBIN REPORT MERCH here: https://daverubin.store/ ---------- Today's Sponsors: Lean - A powerful weight loss supplement with remarkable results to help lower blood sugar, burn fat by converting it into energy, and curb your appetite. Rubin Report viewers get 20% off plus free rush shipping off their first order! Go to: https://TakeLean.com and enter promo code RUBIN for your discount

TIMESTAMPS: 0:00 CLICKBAIT, EREWHON, VLOGGING, SHADOWBANNING, DISNEY 5K, FNAF9:00 TRISHA PLAYED FORTNITE, SPENDING ON SKINS, PHILANTHROPY, DEI, GLOVING18:00 90 DAY FIANCE, COLTON CHEATS35:00 DEMI LOVATO COOKBOOK, OSCAR'S GIFT BAGS45:00 NARA AND LUCKY SMITH, DIAPERS, PERIODS, JAKE SHANE58:40 TIMOTHEE CHALAMET BACKLASH CONTINUES, KYLIE JENNER'S ACTING CAREER1:05:00 MAN TAKES SECRET PHOTOS OF ARIANA GRANDE IN HER HOME1:14:00 CHAPPELL ROAN PAPARAZZI, BRITNEY SPEARS1:30:00 TIMOTHEE AND KYLIE CONT., THE BEAUTY, JFK JR, OZEMPIC, DOJA CAT1:44:00 HUDSON WILLIAMS, CONNOR STORRIE, HEATED RIVALRY, DMING CELEBRITIES LIVE2:00:00 BAYWATCH REBOOT, NOAH BECK, MALIBU FIT MAXX2:16:00 KAI TRUMP EREWHON VLOG CONTROVERSY Learn more about your ad choices. Visit megaphone.fm/adchoices

SlimFast remembers when he was Lazlos' twink, and Lazlo's involved with an investigation. Kathy Ireland is now poor. How does Lazlo feel about Joe Burrow dating Jessica Alba? Why do people go on float trips?? SlimFast gives updates on the current conflict in Iran. Mike DeRosa didn't ‘misspeak,' he tried covering his mistake. The guys who made Ozempic are going broke. Stream The Church of Lazlo podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!

O mercado mudou e o consumidor está mais consciente do que nunca. Por que marcas como a Tirolez estão lançando requeijão com 17g de proteína?No vídeo de hoje, Gu e Bea Furtado discutem a sofisticação de mercado e como você pode usar o conceito de "Mecanismo Único" para não ser esmagado pela concorrência de preço. Analisamos casos reais como o do Super Coffee, Ozempic e a evolução dos cursos online, que deixaram de ser "baratinhos" para se tornarem produtos de alto valor. Aprenda como adaptar o seu negócio aos novos padrões de consumo e usar a Inteligência Artificial para analisar o seu nicho.

0:00-1:00 – Show Open1:00-4:00 – Dave was freaked out by lightning this morning4:00-6:00 – AI video of Cort being suck out of the window by tornado6:00-10:00 – Fair wand for tapping your credit card10:00-13:00 – 80-year-old man redeems free oyster offer with 99-year-old dad13:00-20:00 – The CEO of Burger King is changing the fries20:00-38:00 – Heinz machine that lets you mix your own condiments38:00-42:00 – Guy went into college dorm to film students in shower42:00-50:00 – Amazon driver confronted by customer at end of long rural driveway50:00-52:00 – Old guy rescued from burning car after crash52:00-55:00 – Old person crashed into apartment55:00-57:00 – Waymo stopped just before train crossing57:00-1:02:00 – Hiker rescued after becoming dehydrated1:02:00-1:08:00 – NFL player accused of murder and used ChatGPT to help plan it1:08:00-1:11:00 – Miami Heat player scored 83 points1:11:00-1:15:00 – Guy who tripped at finish line accidentally ran wrong way during race1:15:00-1:17:00 – Woman suing over baseball that hit her1:17:00-1:21:00 – Man suing after being knocked unconscious by full can of beer at Jason Aldean show1:21:00-1:25:00 – Kevin Federline out of money1:25:00-1:28:00 – Richest celebs in the world1:28:00-1:37:00 – Things that terrified you as a kid in the 80s1:37:00-1:40:00 – Woman broke into house and ate Fruity Pebbles1:40:00-1:45:00 – Woman attacked after confronting person who was parking in her paid spot1:45:00-1:54:00 – Guy vacationing in Vegas stung by scorpion in hotel1:54:00-1:58:00 – Mountain lion attacks while people are in hot tub1:58:00-2:24:00 – Foot doctor busted taping his employees in bathroom (what was your inappropriate doctor encounter?)2:24:00-2:29:00 – Guy high on mushrooms arrested hours into 18th birthday2:29:00-2:35:00 – Guy robbed by woman he brought back to hotel room2:35:00-2:38:00 – 2 ladies try to sneak contraband into prison attached to crows2:38:00-2:44:00 – Man claims that Ozempic left him legally blind2:44:00-2:46:00 – Premium chocolate sales increased for people on weight loss drug medication2:46:00-2:50:00 – Buffalo Wild Wings introducing chicken flavored espresso proteini2:50:00-2:55:00 – Frambled Egg trend2:55:00-2:57:00 – Tomato engineered to smell like buttered popcorn2:57:00-3:00:00 – Fight on plane mid-flight3:00:00-3:03:00 – Baby getting locked in EV after faulty battery3:03:00-3:06:00 – Guy used ChatGPT to sell his house3:06:00-3:10:00 – Police robot dogs patrolling streets of Atlanta3:10:00-3:12:00 – Co gallstones become valuable3:12:00-3:16:00 – Retirement home for penguins3:16:00-End – Badass teen subdues man with axe See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's been a long time coming…This week Michael Malice (“YOUR WELCOME”) welcomes world-famous nutritionist and fitness expert, Jillian Michaels, onto the show to talk about the rise (and likely causes) of early-onset cancer, how Big Ag and Big Food strategically designed the obesity crisis, and the dirty truth about the Ozempic craze. Jillian and Michael also share their story on how they first met, and Michael's surprising revelation from it. https://x.com/JillianMichaelshttps://www.instagram.com/jillianmichaels/https://www.youtube.com/c/jillianmichaelsPre-Order UNWANTED – A TALE OF THE OLD WEST AND THE NEW WAVE: https://UnwantedBook.comOrder THE WHITE PILL: http://whitepillbook.com/Order THE ANARCHIST HANDBOOK: https://www.amzn.com/B095DVF8FJOrder THE NEW RIGHT: https://amzn.to/2IFFCCuOrder DEAR READER: https://t.co/vZfTVkK6qf?amp=1https://twitter.com/michaelmalicehttps://instagram.com/michaelmalicehttps://malice.locals.comhttps://youtube.com/michaelmaliceofficialIntro song: "Out of Reach" by Legendary House Cats https://thelegendaryhousecats.bandcamp.com/The newest episode of "YOUR WELCOME" releases on iTunes and YouTube every Wednesday! Please subscribe and leave a review.This week's sponsors: OneSkin – Transforming Skin and Hair at the Cellular Level: Get 15% off OneSkin with the code Malice at https://www.oneskin.co/Malice #oneskinpodPlutoTV – Streaming TV: https://www.Pluto.tv (Free TV) The Pendragon Cycle - Rise of the Merlin: https://www.pendragonseries.com (Streaming now only on DailyWire+)ZBiotics – Pre-Alcohol, Probiotic Drink: Go to https://zbiotics.com/MALICE and use MALICE at checkout for 15% off any first time orders of ZBiotics probioticsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Ozempic weight loss drug promises rapid weight loss, but at what cost? In this video, find out why I would never take Ozempic, the Ozempic dangers they never tell you about, and the semaglutide side effects that will make you think twice about taking Ozempic. Download Dr. Berg's Free Daily Health Routine: https://drbrg.co/45qtO070:00 Introduction: Ozempic explained0:39 Ozempic muscle loss2:15 Natural GLP-1 system2:39 GLP-1 drug side effects4:30 How to avoid Ozempic dangers 10:27 Ozempic truth and the problem with modern medicine11:35 What to do instead of OzempicWhen you lose 50 pounds on Ozempic, you haven't only lost fat; you've also lost muscle. Research has shown that most people gain two-thirds of their weight back within a year of quitting Ozempic. This new weight gain is nearly all fat!Ozempic hijacks a system that already occurs naturally in your body. There are specialized cells in the digestive system called L-cells that increase GLP-1 when stimulated. GLP-1 tells the brain it's no longer hungry, releases insulin, and slows digestion. For many people, the natural GLP-1 system is broken. To activate this system without the use of Ozempic, you'll need to naturally trigger the L-cells and activate GLP-1. This won't work as powerfully as Ozempic, but it can create a significant effect. To do this, consume the following:• Short-chain fatty acids • Apple cider vinegar• Fermented foods • Fiber with each meal• Omega-3 fats • Olive oil• Avocado oil • Amino acids • Bile salts (TUDCA)There are specific types of fiber that help support this process, including inulin found in garlic and onions, leeks, asparagus, artichokes, flax seeds, chia seeds, and avocados. Try replacing salad with sauerkraut to activate GLP-1. Modern medicine does not address root causes, but rather addresses symptoms that occur later in the chain of events. This holds true for Ozempic. Instead of taking Ozempic, try the following:1. Protein and fiber 2. Eliminate starches and sugar from your diet3. Walk after meals4. Consume 1-2 meals per day, no snacking5. Weight trainingDr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

In this episode, Mike provides a simple way to figure out if something is going to be beneficial for your health or is just misinformation. With so much noise out there about what you "should or shouldn't" be doing, it's important to have filters and guardrails in place to keep you focused on what actually matters. This episode will provide you those filters and guardrails. ------------------------------------------------Click here to apply for coaching!For some amazing resources and to be a part of a badass community, join our FB group HEREThe personality assessment is now available online! Click here to take the assessment and find out what your personality tells us about the way you should be training and eating.Take the assessment here!To learn more about Neurotyping, visit www.neurotypetraining.comFollow Mike on IG at @coach_mike_millner

GLP-1 drugs like Ozempic and Wegovy are changing more than just waistlines—they're disrupting the grocery aisle. JMR Co-Editor Brett Gordon speaks with Sylvia Hristakeva (Cornell), Jura Liaukonyte (Cornell), and Leo Feller (Numerator) about their paper, "The No Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food Demand.” The study linked GLP-1 usage survey data to 150,000 households' purchase data, finding that grocery spending declines by approximately 5% within six months, concentrated in processed, calorie-dense categories. Spending reverts to pre-adoption levels upon stopping the medication. In the episode, you'll hear how quickly the project came together and the challenges of working on such a high-profile topic.Paper on SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5073929Paper at JMR: https://journals.sagepub.com/doi/10.1177/00222437251412834

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, "Lyla's Law" Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdown Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. I am definitely feeling better – that lingering cold is gone – but whew still recovering from non stop travel for the past five weeks. I have a great strech of time her at home, then going to Vegas for Brekathorugh T1D at the end of the month and we have two club 1921 events in April – Atlanta and Philly. Before we jump into the news – I need your community commercials! These have been a lot of fun, I announced them late last year – your voice on the show. All the instructions it's very easy in the show notes. Okay.. our top story this week: XX A biotech company developing stem-cell treatments for type 1 diabetes has announced a new research partnership aimed at improving the survival of transplanted insulin-producing cells. NewcelX, a clinical-stage company based in Switzerland, said it will work with Eledon Pharmaceuticals to study a combination approach. The goal is to help transplanted cells survive longer in the body by reducing the immune response that often leads to transplant rejection. If successful, the strategy could support longer-lasting islet cell replacement and move the therapy closer to becoming a functional treatment for people with type 1 diabetes. However, the companies have not yet released any safety or effectiveness data on the combination treatment, and financial details of the partnership were not disclosed. The research agreement is focused on exploring whether combining stem-cell-derived islets with targeted immune therapy can lead to longer-lasting cell transplants and improved outcomes for people with type 1 diabetes. https://www.stocktitan.net/news/ELDN/newcel-x-announces-strategic-collaboration-with-eledon-d10l1vqdofls.html XX Debate this week in the UK on whether testing for type 1 diabetes should become mandatory when children present with symptoms. The Westminster Hall debate, scheduled for 9 March, will consider calls for routine testing of babies, toddlers and young children who show signs associated with the condition. It follows a petition backing the move, dubbed 'Lyla's Law', which passed 121,000 signatures in December 2025. The campaign was launched by John Story after his two-year-old daughter, Lyla, died from diabetic ketoacidosis (DKA) on 3 May 2025, 16 hours after being diagnosed with tonsillitis. https://www.nursinginpractice.com/clinical/diabetes-and-endocrinology/diabetes-community-urged-to-call-on-mps-to-attend-lylas-law-debate/ XX     A new study suggests that people with gestational diabetes who adjust their own insulin doses may reach healthy blood sugar levels faster than those whose doses are adjusted by clinicians. Half of the participants were assigned to adjust their own insulin doses using a simple rule: increase the dose by two units if fasting blood glucose was above 95 mg/dL, decrease it by two units if it dropped below 70 mg/dL, and keep the same dose if levels fell in between. The other half had their insulin adjusted by clinicians through weekly reviews. By the end of pregnancy, both groups had similar average fasting glucose levels before delivery: about 89 mg/dL in the patient-led group and 90 mg/dL in the clinician-led group. However, those adjusting their own insulin reached their blood sugar targets more quickly, averaging 1.8 weeks compared with 2.5 weeks for those managed by clinicians. The study also found lower risks of certain complications among the patient-led group. https://www.medscape.com/viewarticle/self-insulin-dosing-leads-control-gestational-diabetes-2026a1000729 XX   A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries.   Semaglutide, the active molecule in Novo Nordisk's Ozempic and Wegovy will lose patent protection in countries such as Brazil, China, and India later this month, and researchers identified 150 countries where it was never patented. These researchers estimated it will cost as little as $3 to produce a month's supply of semaglutide, which in its branded form sells for around $200 a month in the United States. Another of the study's authors, Professor Francois Venter at the University of Witwatersrand in South Africa, said drugs to treat HIV, TB, malaria, and hepatitis are now available at prices close to production costs but still sufficient for generic manufacturers to operate. https://www.sciencealert.com/weight-loss-drugs-could-cost-just-3-a-month-to-make-as-patents-end XX Here in the US the FDA is stepping up its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting telehealth companies it says make "false or misleading" claims about compounded versions of popular obesity drugs. The FDA says Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA's approval process." https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters XX   Check your infusion sets for an issue: Unomedical, a subsidiary of Convatec and a supplier of insulin infusion sets to diabetes tech firms, has received a warning letter from the FDA. Inspectors raised concerns with leaking infusion sets, following a regulatory assessment of Unomedical's facility in Reynosa, Mexico, last summer. Unomedical supplies infusion sets to insulin pump makers including Medtronic, Tandem Diabetes Care and Beta Bionics. In a Feb. 3 statement, Convatec said the letter focuses on reporting procedures and quality protocols and does not place restrictions on producing, marketing or distributing any of Unomedical's products.  Unomedical told the FDA in its responses that it plans to conduct a retrospective review of complaints involving serious injury or death by January and conduct additional training on complaint handling by May.   https://www.medtechdive.com/news/fda-warns-insulin-infusion-set-maker-unomedical-over-leaks-mishandled-comp/813503/ XX Nearly four in ten people with type 2 diabetes do not take their medications as prescribed, according to a new research review published in Diabetologia in November 2025.   Researchers examined existing studies on medication adherence, including how often patients miss doses, why it happens, and what strategies may help. They estimated that about 38% of patients with type 2 diabetes are not fully adherent to their medications.   Adherence rates vary depending on the type of medication. About 63% to 68% of patients take oral glucose-lowering drugs as directed, while adherence drops to 43% to 54% for injectable GLP-1 medications and 41% to 64% for insulin.   Poor adherence can lead to serious consequences. One retrospective study cited in the review found that patients who consistently took their glucose-lowering medications had a 31% lower risk of hospitalization or emergency department visits.   The review also highlighted ways to improve adherence. Simplifying medication routines can help, such as using fixed-dose combination pills, which combine multiple drugs into a single tablet. Studies show these combinations are linked to better adherence and improved blood sugar control.   Pharmacists can also play an important role by providing education, reviewing medications, setting up reminders, and helping patients organize their treatment plans. The researchers noted that support should be tailored to each patient. Older adults may benefit from simpler systems and caregiver support, while younger patients may respond better to digital tools like app-based reminders.   The authors also found that measuring adherence is challenging and recommend using multiple methods, such as pharmacy records, patient interviews, and objective tests when possible.   Overall, the review concludes that personalized, multi-step approaches lasting at least three months are most effective in helping people with type 2 diabetes stay on track with their medications. https://www.pharmacytimes.com/view/type-2-diabetes-medication-adherence-rates-remain-low-and-pharmacists-can-help XX New clinical trial shows metformin does not directly reverse insulin resistance in people with type 1 diabetes. Instead, it lowers the total amount of insulin required to keep blood glucose levels within the recommended range. The findings, published in Nature Communications, challenge long-held assumptions about how metformin works in type 1 diabetes. The results may help physicians refine treatment strategies and reduce the daily demands placed on people who rely solely on insulin therapy. "Insulin resistance is a growing problem in type 1 diabetes. Not only does it make regulating blood sugar levels difficult, but it is an underappreciated risk factor for heart disease, which is one of the biggest causes of health complications and deaths in those with type 1 diabetes," says Dr. Jennifer Snaith, endocrinologist and co-lead of the study.   https://scitechdaily.com/groundbreaking-trial-reveals-unexpected-benefit-of-metformin-in-type-1-diabetes/   Tech news ahead, including updates from Sensonics, Dexcom & Tandem.. right after this…. Back ot the wnews.. XX Sensonics shares that it's secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in the second half of 2026. Gemini builds on the implanted CGM to put the transmitter under the skin as well as the sensor. https://www.drugdeliverybusiness.com/senseonics-q4-2025-ide-gemini-cgm/ XX Medtronic Diabetes is now officially MiniMid, a stand alone public company. Medtronic  acquired MiniMed 25 years ago announed last May that it would spin its diabetes business off. In their statement the company points out that MiniMed is the only diabetes tech company to sell both insulin pumps and continuous glucose monitors.   https://www.investing.com/news/stock-market-news/medtronics-diabetes-unit-minimed-valued-at-53-billion-as-shares-fall-in-nasdaq-debut-4547518 XX Kevin Sayer heads back to Dexcom.. The former CEO is back in his position as executive chair of the Board, he'd stepped away for a medical leave. Dexcom (Nasdaq:DXCM) announced today in an SEC filing that former CEO Kevin Sayer has returned from his leave of absence. Sayer's return to the board comes just days after Dexcom announced a new board member. Last week, the company announced that it added Google SVP, Platforms and Devices, Rick Osterloh, to its board as well.     https://www.drugdeliverybusiness.com/kevin-sayer-returns-dexcom-board-chair/ SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Rick Osterloh to its Board of Directors, effective today, according to a press release statement.   Osterloh serves as Senior Vice President, Platforms & Devices at Google, where he oversees Android, Google Play, Chrome, and Google's hardware portfolio including Pixel phones, Google Nest devices, and Fitbit wearables. He has held this position since 2016.   https://www.investing.com/news/company-news/dexcom-appoints-google-executive-rick-osterloh-to-board-93CH-4529662 XX Sequel Med Tech announced broad national availability of its twiist™ Automated Insulin Delivery (AID) System powered by Tidepool. After U.S. FDA clearance in 2024 and a controlled launch to optimize the twiist experience, the system is now fully available nationwide. The release says: Built on Sequel's proprietary iiSure™ Technology, the system enables earlier detection of delivery issues, alerting users to blockages up to nine times faster than other AID systems1, potentially reducing the risk of unexplained high glucose and giving you time to take action before experiencing severe high blood sugar or DKA2. Designed to expand access to automated insulin delivery, twiist is available through pharmacy channels with a flexible access model, XX Tandem Diabetes Care's Mobi automated insulin delivery system is now available with Android devices. In November, Tandem announced that it received FDA approval for the Android version of its Mobi mobile app. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software. At the time of the clearance, it said it would commence a limited rollout before the full launch — now underway — this year.   Tandem launched Mobi in the U.S. in February 2024. It initially received FDA clearance for people with diabetes ages six and up in July 2023. The system then received expanded clearance for pediatric indications in April 2024, then later won CE mark in May 2025.   Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the flagship Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve. https://www.drugdeliverybusiness.com/tandem-diabetes-care-launches-mobi-android/

March 10, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Novo Nordisk drops patent case against Hims & Hers as companies reach agreement for Hims to offer FDA-approved Ozempic and Wegovy at standard pricing Whoop introduces hormone biomarker testing for 11 hormonal markers combined with wearable data and AI-driven insights as women become fastest-growing user segment Fitt Insider releases Scouting Report highlighting 50 early-stage startups shaping wellness across mental, physical, social, environmental, and existential health Today's episode is brought to you by AIIR — a modern communications and experiential agency for health, wellness, fitness, and performance brands. From earned media to events and creator-led campaigns, AIIR helps companies sharpen their story, earn attention, and build trust that compounds. Visit aiir.agency to learn more. More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

We chew through billions of sticks of gum annually. In fact, about half of the entire U.S. population chewed gum in the last year. And while many today envision it strictly as just another modern checkout aisle impulse purchasing decision…the history of chewing gum is a wild story of accidents, war rations, social distancing demand drops, and a bizarre resurgence in the era of Ozempic. Although understanding chewing gum's past makes its functional future seem even more inevitable. Consequently, every multibillion-dollar ingestible CPG category is in the early innings of a remarkable transformation, as consumers are moving closer everyday towards this four-way intersection of taste, convenience, nutrition, and functionality. Therefore, it shouldn't surprise anyone to learn that even chewing gum brands have begun competing for consumer attention with wellness-focused marketing and functionality of ingredients. Don't believe me? Well, look no further than strategic actions by the market leader. In early 2024, Mars Wrigley started repositioning a few of its key gum brands as an "instant stress reliever" to target Gen Z and Millennials who prioritize mental wellness. Also, largely due to the format popularity (and effectiveness) of nicotine-replacement therapy (specifically Nicorette) eventually becoming available over the counter in 1996…chewing gum started gaining traction as an innovative nutraceutical ingredient delivery system several years later when a federal grant enabled research into caffeinated gum for the U.S. military. Thus, it probably shouldn't surprise anyone either that (in terms of functionality of ingredients), “energy & focus” is the most sizable segment within the rapidly growing functional gum category. In fact, based on the 52-week period ended January 25, 2026…dollar sales of caffeinated gum reached $340 million (increasing around 7% YoY). And while even Wrigley's launched a (more defunct) caffeinated gum competitor more than a decade ago, the prominent brands currently in the “energy & focus” functional gum subcategory include NEURO and REV. Although “energy/focus” functional gum is emerging as a compelling alternative to the crowded RTD energy market…not only because it offers a more portable, lightweight alternative to energy drinks (or coffee), but it also takes effect faster. Nevertheless, the new age of gum is here…and it's infused with functional benefits beyond the masticating joy that traditional chewing gum provided forever. So, for this next part of this content, I wanted to explore a few emerging opportunities within this bold new world of functional chewing gum. Also, I believe it's important to take a step back and consider why functional gum…or more broadly, water-free direct-to-mouth delivery systems (like fast-melt powders, chewable fast-disintegrating tablets, and effervescent fizzing granules) are rising in popularity. Consumers are increasingly tired, inconsistent, and overwhelmed by traditional dietary supplement formats. And this “format fatigue,” along with consumers' looking to eliminate friction from modern routines, is creating an opportunity for water-free, direct-to-mouth delivery systems that eliminate prep, improve convenience, enhance the sensory experience. Moreover, these benefits make direct-to-mouth formats not just consumer-friendly, but also strategically valuable for functional CPG brands looking to meaningfully differentiate and breakthrough crowded categories.

Dans cet épisode du podcast La Pause Fitness nous allons parler d'un complément vendu pour la concentration qui pourrait raccourcir la vie des hommes, un miel au chocolat sorti d'un labo brésilien, l'additif caché dans l'Ozempic oral qui dérange le microbiome, et ce que 5 000 centenaires chinois nous apprennent sur la viande et le […] The post Ce complément vendu pour la concentration raccourcirait la vie des hommes, le miel au chocolat miracle ou arnaque, et Ozempic en pilule : ce que les études disent vraiment appeared first on Fitnessmith.

Dr. Peter Brukner is one of Australia's most decorated sports medicine physicians. He is former head of medical and performance at Liverpool FC, team doctor for Cricket Australia, Cathy Freeman's doctor at the Sydney 2000 Olympics, and now one of the most credible voices in the low-carb and diabetes reversal space.In 2012, at 60 years old and working in Liverpool, Brukner had a fatty liver, high triglycerides, elevated insulin, and a strong family history of type 2 diabetes. He tried a low-carb diet for 90 days. He lost 13 kilograms. Every blood marker normalised. The fatty liver (present for a decade) was gone.What followed was a complete reorientation of his career: founding Sugar by Half, writing the bestselling 'A Fat Lot of Good', developing the Defeat Diabetes program, and becoming one of the most persistent critics of dietary guidelines that he believes are built on fraudulent science.This is a wide-ranging, evidence-dense conversation covering the politics of how fat got demonised, why the medical system structurally cannot update itself, the real mechanism behind type 2 diabetes, the legitimate and illegitimate uses of GLP-1 drugs like Ozempic, athlete nutrition, injury recovery, and where AI is headed in medicine.Watch all of our interviews at https://discernable.io/interviews

Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years.   Resources: Follow Andrew Huberman on X: https://twitter.com/hubermanlab Follow Daisy Wolf on X: https://twitter.com/daisydwolf Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

You can't watch a single sporting event without being hit with an Ozempic commercial — but did you know that those GLP-1s everyone's talking about are actually peptides? Kyal Van Der Leest — nutritionist, naturopath, and the formulator behind LvLUp Health — breaks down which peptides actually work, which ones are all hype, and why the Swiss Army knife of peptides (BPC-157) might be exactly what your gut, your joints, and your brain have been begging for. Kyal gets into the oral vs. injectable debate (Kyal sells oral peptides and still admits most oral ones don't work — gotta respect that), why your midlife body composition changes aren't just about willpower, the mould exposure conversation that'll make you side-eye your hotel room forever, and whether microdosing GLP-1s is the smarter play. If you're a Betty navigating perimenopause or menopause and want real, science-backed options beyond "just take Ozempic," this episode is your new best friend. Go to https://lvluphealth.com/DRSTEPHANIE and use code DRSTEPHANIE for 15% off. Episode Overview:0:00 Teaser/Intro6:30 Oral vs. Injectable Peptides11:22 The Cost, Convenience & Travel Factor15:47 BPC-157: The Swiss Army Knife of Peptides21:10 Arthritis, Autoimmunity & the Gut Connection27:28 GHK-Copper: Skin From Within & Longevity Genes35:54 Body Composition Changes in Perimenopause & Menopause43:24 Microdosing GLP-1s49:47 Mould: The Hidden Wrecker of Hormones, Gut & Brain58:49 How to Cycle Peptides (And Why You Should)1:02:38 Level Up Health: Where to Find These Products1:09:29 The After Party: Dr. Stephanie's Honest Take Resources mentioned in this episode can be found at https://drstephanieestima.com/podcasts/ep459 We couldn't do it without our sponsors: TIMELINE  - As perimenopausal women, we know we are in a fight against time to preserve our muscle strength and endurance, plus our recovery needs are greater. That's why you save 20% at https://timelinenutrition.com/better with code BETTER. JUST THRIVE HEALTH - Take the Just Thrive FEEL BETTER challenge today, and save 20% on your first order. Go to https://justthrivehealth.com/better and use the code BETTER to see the difference for yourself. BON CHARGE - Achieve glowing skin, gain more energy, and uplevel your recovery practice with a suite of red light products. Get 15% off at https://boncharge.com/better with code BETTER. AGZ - If you're ready to turn down the stress and focus on the rest, head to https://drinkag1.com/STEPHANIE to get a FREE Frother with your first purchase of AGZ. EQUIP COLLAGEN - Support bones, joints, gut, and skin with Equip Collagen. Get 20% off at https://equipfoods.com/better with code BETTER. ****************************P.S. When you're ready, here are two ways Dr. Stephanie can help you:Subscribe: The Mini Pause — My weekly newsletter packed with the most actionable, evidence-based tools for women 40+ to thrive in midlife.Build Muscle: LIFT — My progressive strength training program designed for women in midlife. Form-focused, joint-friendly, and built for real results. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The first episode of Skinny Inc. was all about the science behind GLP-1s, and the second episode was about the business, from the pharmaceutical companies who make GLP-1s to the insurance plans that may or may not cover it. Today, we're exploring how the so-called “Ozempic era,” affects people's mental health. First, business owner Maiyhet Burton tells us how using a GLP-1 has helped her body image. Globe health reporter Kelly Grant details how experts are split on the effect of GLP-1s on weight stigma, and psychotherapist Zoë Bisbing explains how the body positive movement helps her clients. Plus, Tigress Osborn, executive director of the National Association to Advance Fat Acceptance on why the popularity of GLP-1s shows how far we have to go with anti-fat discrimination, and Ary Mahraj and Emily Donahue from the National Eating Disorder Information Centre tell us how people with eating disorders may be impacted by the constant discussions about weight loss. Finally, Dr. Stephen Glazer, Medical Director for the Bariatric Surgical Program at Humber River Hospital in Toronto on how weight stigma can be internalized. You can contact the National Eating Disorders Information Centre at their toll-free helpline at 1-866-NEDIC-20 or visit their website. Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you're on Wegovy, Zepbound, Ozempic, or Mounjaro — and worried about what happens when you stop — this episode is for you. The fear of gaining it all back is real. But weight regain is not inevitable. It's manageable. And I'm going to show you how. "What happens when you stop your GLP-1?" This is one of the most common questions I get in my clinic every single week. It's time I answered it publicly — with science, not fear. In this episode, I break down exactly what happens in your body when you stop your GLP-1, why weight regain happens, and the five pillars you need to protect your results, whether you're stopping by choice or out of necessity. Listen now! Episode Highlights: The physiological reason hunger surges and metabolism slows when you stop GLP-1s  What the SURMOUNT-4 clinical trial tells us about weight regain after stopping Tirzepatide Who is at highest risk for regaining weight  The 5 pillars of weight maintenance: protein, resistance training, carb awareness, appetite retraining, and medication transition strategy Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

This week on Health Talk America presents ‘The Dr. Bob Martin Show', Dr. Adam Brockman divesheadfirst into the science behind your daily headlines— We're unpacking the new Alzheimer's Molecular Atlas that proves the brain's chemistry is far more complex than any one “bad protein,” and why your favorite bubble tea might come with a side of heavy metals. Plus: the double‑whammy risk of insomnia plus sleep apnea, the truth about Ozempic's gut effects, and a breakthrough look at iron nanomaterials targeting cancer cells like guided missiles.Special Guest: Dr. David Heitmann, Functional Medicine Doctor and “Wellness Tech” ExpertHealth Headlines of the WeekHealth Alternative of the WeekHealthy Mystery of the Week

Megyn Kelly is joined by Jesse Kelly, host of "I'm Right," to discuss the high-stakes Texas GOP Senate primary between John Cornyn and Ken Paxton, President Trump game-changing endorsement in the race, why this could be the chance for Texas to help drain the swamp, Gavin Newsom melting down when asked a simple question about his main political project, Newsom's ramblings about Gandhi and Mandela, Katie Couric asking Newsom if he's too hot to be president, how the current conflict with Iran is in the “break things” phase of war, the much harder questions of what happens when it's time "make things" and rebuild, and more. Then Mark Halperin, host of "Next Up," joins to discuss the real reason Kristi Noem was fired from DHS, whether her rocky congressional hearing and relentless negative coverage became the final straw for President Trump, the truth about infighting with top officials in the Trump admin, why Gavin Newsom's profile as a straight, white, Christian, tall man could help him win the 2028 Democratic nomination, his struggles explaining his political vision on his current media tour,  the growing trend of celebrities using Ozempic for extreme weight loss, why stars like Oprah Winfrey and others now appear shockingly thin, and more.   Subscribe to Mark's show Next Up: Apple: https://podcasts.apple.com/us/podcast/next-up-with-mark-halperin/id1810218232 Spotify: https://open.spotify.com/show/2f0n8G4xqUo8aGxbbbtRjH YouTube: https://www.youtube.com/@nextuphalperin?sub_confirmation=1   Kelly- https://jessekelly.com/   Ethos Life Insurance: Protect your family's future with fast, online life insurance from Ethos—get a free quote in minutes at https://Ethos.com/MK Relief Factor: Break up with pain—Relief Factor targets inflammation so you can move better and feel better; try the 3-Week QuickStart for just $19.95 at https://ReliefFactor.com or call 800-4-RELIEF. Dose: Support your liver and daily energy with Dose for Your Liver—get 35% off your first month at https://dosedaily.co/MK or use code MK at checkout. Herald Group: Learn more at https://GuardYourCard.com     Follow The Megyn Kelly Show on all social platforms: YouTube: https://www.youtube.com/MegynKelly Twitter: http://Twitter.com/MegynKellyShow Instagram: http://Instagram.com/MegynKellyShow Facebook: http://Facebook.com/MegynKellyShow  Find out more information at:https://www.devilmaycaremedia.com/megynkellyshow Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 drugs like Ozempic, Wegovy, and semaglutide are everywhere right now and so is the fear surrounding them. Are they dangerous? Are they a breakthrough? And why is the internet so divided?Today I'm joined by Drs. Mark and Michele Sherwood from the Functional Medical Institute to talk honestly about what GLP-1s actually do, who they're designed to help, and why so much of the conversation online is driven by hype and fear instead of facts.We also dive into ketones, blood sugar and mood swings in kids, snoring and sleep apnea, hormones for men in their 40s, cold plunges and saunas, and why so many people are struggling with anxiety right now. Most importantly, we talk about how to become “hope dealers” in a culture that profits from fear.If you're looking for clear thinking, practical health wisdom, and encouragement in a noisy world, this episode is for you.Prime Sponsor: No matter where you live, visit the Functional Medical Institute online today to connect with Drs Mark and Michele Sherwood. Go to homeschoolhealth.com to get connected and see some of my favorites items. Use coupon code HEIDI for 20% off!Show mentions: http://heidistjohn.com/mentionsWebsite | heidistjohn.comSupport the show! | donorbox.org/donation-827Rumble | rumble.com/user/HeidiStJohnYoutube | youtube.com/@HeidiStJohnPodcastInstagram | @‌heidistjohnFacebook | Heidi St. JohnX | @‌heidistjohnFaith That Speaks Online CommunitySubmit your questions for Fan Mail Friday | heidistjohn.com/fanmailfriday

Trump declares Claude a supply-chain risk, boner bears, Thai ladyboy does a dirty job, Tyler Oliveira booted from Patreon, British children are terrorists, California age gates calculators, fires in Texas, the Turkey Tom retraction, Chantal's hallway duck, iDubbbz cries, Gooseworx inflates something, Fatrick builds a mocktail app, Jet Neptroon is on Ozempic, ShortFatOtaku's 20-year revenge fantasy against a child, Daniel Larson is competent, and Anthony Cumia meets a fan.

Chef serve menu Ozempic.

Vivian Wilson became the talk of Milan Fashion Week when she seductively walked the runway of Demna's debut Gucci show in a floor-length white gown. The 21-year-old model said she was briefed by casting to embody Venus, the Roman goddess of love. Her path to the Gucci runway began with a casting tape filmed in her own driveway. She walked "like a crazy person, like 8 million times" until she had the perfect take. The result? She ended up positioned in the lineup between icons Kate Moss and Mariacarla Boscono. "When I found that out, I was shaking in my boots," she told Chloe Malle, cozy in a Paris hotel room, while recording today's episode of The Run Through. "We did it, though."Before all the fashion week glamour in Paris and Milan, there was a very different life. Wilson spent time studying Japanese at a university in Tokyo, with plans to earn her TEFL certificate and become an ESL teacher. A Teen Vogue cover changed everything. "It completely transformed my career," she said. Now she's in Paris, doing the model thing — castings every hour, NDAs on NDAs — and entirely at peace with the pivot. "I wanna see how big I can get,” she said. “We're just locking the fuck in."The conversation took a more serious turn when Malle raised the question of whether models look markedly thinner this season than even five years ago. Wilson didn't hesitate. "It's the Ozempic apocalypse, girl. I am so fucking over this." Off the catwalk, she reads gay fantasy fiction and has a passion for Excel spreadsheets. She is trans, a John Oliver devotee, and has genuine ambitions in voice acting. Her three wishes are to appear in Vogue, attend the Met Gala, and walk for Schiaparelli. She left the hotel room with a piece of the chocolate Eiffel Tower, having resolved to break off a piece from the middle so as "not to compromise its structural integrity."Also in the episode, Vogue editors share thoughts from the Balmain, Dries Van Noten and Saint Laurent shows at Paris Fashion Week.The Run-Through with Vogue is your go-to podcast where fashion meets culture. Hosted by Chloe Malle, Head of Editorial Content, Vogue U.S.; Chioma Nnadi, Head of British Vogue; and Nicole Phelps, Director of Vogue Runway, each episode features the latest fashion news and exclusive designer and celebrity interviews. Learn about your ad choices: dovetail.prx.org/ad-choices

GLP-1 medications are evolving quickly.There's no longer just Ozempic and Mounjaro. There are more than five types of the drugs across at least one dozen different brands.Plus, a new pill version is hitting the market, which is easier to administer than the shots.As the drugs get cheaper and easier to take, people are asking questions about potential side effects, long-term safety and regulation.Some experts are also asking how appetite-suppressing medications are changing our relationship with food — and what that means for eating disorders and nutritionWe will unpack the updates, benefits and risks from a medical, nutrition and psychological perspective.Guests:Ken Alltucker, consumer health reporter, USA TodayDr. Aradhna Saraswat, physician/assistant professor, Center for Women's Health, Wexner Medical CenterZoe Ross-Nash, PsyD, licensed clinical psychologist/certified eating disorder specialist/founder, Equilibrium Health AdvantageIf you have a disability and would like a transcript or other accommodation you can request an alternative format.(photo: David J. Phillip / AP)

Dietitians Aidan Muir and Torwen Eerkens break down GLP-1 medications for weight loss: the different types available; potential benefits and risks; and what to consider for nutrition to optimise health while using GLP-1s. (1:25) What are GLP-1 Medications? (3:53) History of Medications (8:49) Torwen & Aidan's Philosophy on GLP-1s (13:04) Nutrition Considerations for GLP-1 Use (19:25) Supplements to Consider WEBSITE:  https://www.idealnutrition.com.au/ PODCAST:  https://www.idealnutrition.com.au/podcast/ INSTAGRAM:  https://www.instagram.com/idealnutrition__/?hl=en Our dietitians

GLP-1 medications are evolving quickly.There's no longer just Ozempic and Mounjaro. There are more than five types of the drugs across at least one dozen different brands.Plus, a new pill version is hitting the market, which is easier to administer than the shots.As the drugs get cheaper and easier to take, people are asking questions about potential side effects, long-term safety and regulation.Some experts are also asking how appetite-suppressing medications are changing our relationship with food — and what that means for eating disorders and nutritionWe will unpack the updates, benefits and risks from a medical, nutrition and psychological perspective.Guests:Ken Alltucker, consumer health reporter, USA TodayDr. Aradhna Saraswat, physician/assistant professor, Center for Women's Health, Wexner Medical CenterZoe Ross-Nash, PsyD, licensed clinical psychologist/certified eating disorder specialist/founder, Equilibrium Health AdvantageIf you have a disability and would like a transcript or other accommodation you can request an alternative format.(photo: David J. Phillip / AP)

In this episode, Mike provides valuable insight into why rest and recovery is just as important as your training routine. We don't build muscle or lose fat in the gym... we improve by recovering adequately from the work we do in the gym (and the kitchen). There are usually plenty of symptoms that you need more recovery... find out what they are in this episode.------------------------------------------------Click here to apply for coaching!For some amazing resources and to be a part of a badass community, join our FB group HEREThe personality assessment is now available online! Click here to take the assessment and find out what your personality tells us about the way you should be training and eating.Take the assessment here!To learn more about Neurotyping, visit www.neurotypetraining.comFollow Mike on IG at @coach_mike_millner

We're answering listener questions on topics such as the APOE4 gene, weight management with Ozempic, the effectiveness of the Yuka app, Herbalife shakes, and hydration while taking creatine.

Today, we received an update on the ongoing conflict in Iran (Operation Epic Fury). Iran's missile-launching capabilities have been significantly diminished, and the Department of War's offensive operations continue to target Iran's weapons, bases, and leadership. Former President Biden was unable to enlist in the military due to an asthma diagnosis. Additionally, Democrat Jasmine Crockett lost the Texas primary last night to fellow Democrat James Talarico. Mark interviews the Chairman of Forbes Media, Steve Forbes. Together, they analyze Minority Leader Chuck Schumer's criticism of Trump's decision to attack Iran, which Schumer refers to as “Trump's Endless War.” Steve Forbes also discusses the contrast between NYC's and Florida's budgets and politics, noting that the recent spike in gas prices should be temporary. Questions have emerged about the tenure of U.S. Secretary of Homeland Security Kristi Noem, who is facing criticism for reportedly spending over $200 million on self-promotional ads ahead of the midterm elections - even though President Trump may have approved the expenditure. Many restaurants are launching Ozempic-themed menus, while bakeries are seeing a downturn in business as more customers use Ozempic and reduce their portion sizes. As a result, businesses may need to lower prices to attract and retain customers. Mark interviews Journalist Steve Cuozzo. New York City is experiencing a surge in real estate investment, with companies expanding and more vacant offices being filled. There is a growing demand for new restaurants, especially those offering vegan and specialty foods. Steakhouses also remain a popular dining choice for Manhattan residents and visitors.See omnystudio.com/listener for privacy information.

Today, we received an update on the ongoing conflict in Iran (Operation Epic Fury). Iran's missile-launching capabilities have been significantly diminished, and the Department of War's offensive operations continue to target Iran's weapons, bases, and leadership. Former President Biden was unable to enlist in the military due to an asthma diagnosis. Additionally, Democrat Jasmine Crockett lost the Texas primary last night to fellow Democrat James Talarico. Mark interviews the Chairman of Forbes Media, Steve Forbes. Together, they analyze Minority Leader Chuck Schumer's criticism of Trump's decision to attack Iran, which Schumer refers to as “Trump's Endless War.” Steve Forbes also discusses the contrast between NYC's and Florida's budgets and politics, noting that the recent spike in gas prices should be temporary. Questions have emerged about the tenure of U.S. Secretary of Homeland Security Kristi Noem, who is facing criticism for reportedly spending over $200 million on self-promotional ads ahead of the midterm elections - even though President Trump may have approved the expenditure. Many restaurants are launching Ozempic-themed menus, while bakeries are seeing a downturn in business as more customers use Ozempic and reduce their portion sizes. As a result, businesses may need to lower prices to attract and retain customers. Mark interviews Journalist Steve Cuozzo. New York City is experiencing a surge in real estate investment, with companies expanding and more vacant offices being filled. There is a growing demand for new restaurants, especially those offering vegan and specialty foods. Steakhouses also remain a popular dining choice for Manhattan residents and visitors.

Questions have emerged about the tenure of U.S. Secretary of Homeland Security Kristi Noem, who is facing criticism for reportedly spending over $200 million on self-promotional ads ahead of the midterm elections - even though President Trump may have approved the expenditure. At the same time, many restaurants are launching Ozempic-themed menus, while bakeries are seeing a downturn in business as more customers use Ozempic and reduce their portion sizes. As a result, businesses may need to lower prices to attract and retain customers. Mark takes your calls! Mark interviews Journalist Steve Cuozzo. New York City is experiencing a surge in real estate investment, with companies expanding and more vacant offices being filled. There is a growing demand for new restaurants, especially those offering vegan and specialty foods. Steakhouses also remain a popular dining choice for Manhattan residents and visitors.

Questions have emerged about the tenure of U.S. Secretary of Homeland Security Kristi Noem, who is facing criticism for reportedly spending over $200 million on self-promotional ads ahead of the midterm elections - even though President Trump may have approved the expenditure. Many restaurants are launching Ozempic-themed menus, while bakeries are seeing a downturn in business as more customers use Ozempic and reduce their portion sizes. As a result, businesses may need to lower prices to attract and retain customers.

Questions have emerged about the tenure of U.S. Secretary of Homeland Security Kristi Noem, who is facing criticism for reportedly spending over $200 million on self-promotional ads ahead of the midterm elections - even though President Trump may have approved the expenditure. At the same time, many restaurants are launching Ozempic-themed menus, while bakeries are seeing a downturn in business as more customers use Ozempic and reduce their portion sizes. As a result, businesses may need to lower prices to attract and retain customers. Mark takes your calls! Mark interviews Journalist Steve Cuozzo. New York City is experiencing a surge in real estate investment, with companies expanding and more vacant offices being filled. There is a growing demand for new restaurants, especially those offering vegan and specialty foods. Steakhouses also remain a popular dining choice for Manhattan residents and visitors.See omnystudio.com/listener for privacy information.

Questions have emerged about the tenure of U.S. Secretary of Homeland Security Kristi Noem, who is facing criticism for reportedly spending over $200 million on self-promotional ads ahead of the midterm elections - even though President Trump may have approved the expenditure. Many restaurants are launching Ozempic-themed menus, while bakeries are seeing a downturn in business as more customers use Ozempic and reduce their portion sizes. As a result, businesses may need to lower prices to attract and retain customers.See omnystudio.com/listener for privacy information.

The other night, I was at the ER with Javi until 4 am. By the time I got home, the temptation to cancel everything and stay in bed was very real.But with just a few hours of sleep, I still got up, got ready, did my makeup, and showed up for the day.In this episode, I'm talking about the idea of “never looking like what you're going through.” Not in a performative or toxic way, but in the sense of refusing to abandon yourself during hard moments. Sometimes the smallest acts of care, from washing your face, getting dressed, and keeping a routine, are what carry us through the chaos.Show Notes

The Gary & Shannon Show Hour 2 (03/04) - Newsom plays kingmaker, Meta execs exposed in new depositions, and California wine is dying. Newsom endorses Mayor Bass — future cabinet play or a kiss goodbye heading into a fire-scarred re-election? Newsom's Kimmel "tongue bath" for his new book — Shannon says he's trying to be so many people he gets lost in it Two social media trials running simultaneously: LA addiction case + New Mexico depositions revealing never-before-seen Zuckerberg video Meta exec in NM: "we have 2 billion users, how are we supposed to monitor all of them?" while admitting they shadow banned "high-risk" adults California wine industry getting crushed — Gary & Shannon point the finger at Ozempic and the sober-curious movement See omnystudio.com/listener for privacy information.

With the new craze over weight-loss drugs like Ozempic, how should Christians respond? Kevin and Josh talk about God's values vs society's, how humanism naturally leads to worshiping the body — and how we become what we behold. Then they go to the Scriptures for a holistic doctrine of stewardship that helps us to live well, without forbidding foods, turning our bodies into idols, or over-emphasizing the physical at the expense of the spiritual.

We start with the escalating conflict in the Middle East as Donald Trump and Benjamin Netanyahu launch strikes on Iran, raising questions about strategy, casualties, and whether Congress will step in before the situation spirals further.Then we shift to the political fallout from the Epstein files, as new claims about Trump's name appearing repeatedly spark debates about accountability, optics, and whether impeachment would even be possible.The panel also takes a break from the heavy politics for a rapid-fire ranking game: “Even For Trump…” — where the most bizarre and controversial Trump moments go head-to-head.Later, we tackle the BAFTA controversy involving Michael B. Jordan and Delroy Lindo, after a racial slur was heard during the broadcast and later attributed to a Tourette's tic. The big question: does intent change the impact?In The Scoop, we hit quick-fire topics including:• Ray J's latest viral moment• Floyd Mayweather returning to the ring• 50 Cent vs T.I. legacy debate• Drake vs Kendrick Lamar — has the balance officially shifted?Plus, a listener dilemma: Should you call out a family member pretending their Ozempic weight loss is “pure discipline”?Expect sharp debates, strong opinions, and a lot of laughs.

As Jordana prepares for the birth of her second child, she and Dr. Naomi unpack how social media is engineered to spike anxiety, especially as Jordana gears up for labor. One listener writes in about her chronically grumpy father-in-law who's suddenly sunshine and light after starting Ozempic, and she's left wondering what to do with her lingering resentment now that he's a “new person.”  Another Betch has been excluded from a splashy upcoming family vacation and can't decide what stings more: not being invited or the fact that the trip sounds like her personal nightmare. After a stretch of sleepless nights and draining workdays, one woman asks how to stop beating herself up when she just can't seem to lull herself to sleep. A Valentine's Day dinner is interrupted by her brother-in-law's persistent phone calls, leaving another listener questioning whether her irritation is justified. And finally, a new mom finds herself cast as the default babysitter for every baby at a family gathering—and wants validation that her unpaid labor isn't just invisible, it's expected. Learn more about your ad choices. Visit megaphone.fm/adchoices

My new book, "The Weight Loss Cure," offers a step-by-step guide to rebuilding your gut ecosystem so you can restore your body's natural weight-control system — no injections required Your gut produces the same GLP-1 hormone that weight-loss drugs like Ozempic mimic, meaning your body already has the natural machinery for appetite control and fat burning Damage from seed oils and low-fiber diets weakens your gut barrier, disrupts GLP-1 signaling, and causes inflammation that blocks weight loss A key gut bacterium called Akkermansia muciniphila helps repair your gut lining, balance blood sugar, and promote natural fat loss — even in its pasteurized, non-living form Restoring gut health begins with repairing the barrier, reducing linoleic acid intake, and gradually reintroducing diverse fibers to produce "Gut Gems" like butyrate that calm inflammation and stabilize metabolism

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping the treatment of obesity around the world. But even when these medicines are judged “cost-effective”, access often depends on who can afford to pay. In the second episode of our Business Daily series on the global weight-loss economy, Sam Fenwick examines how different countries are funding — or rationing — access to these high-priced injections. In England, the state's National Health System says the drugs offer good value for money, and yet rollout is being phased in slowly because of cost and capacity pressures. In the United Arab Emirates, most patients rely on private insurance or pay out of their own pockets. And in India, where obesity is rising fast, affordability remains a major barrier, although lower-cost generics may soon change that. If these medicines can prevent diabetes, heart attacks and strokes, they might save health systems money in the long run. But right now, governments, insurers and patients are grappling with the same question: Can we afford the weight-loss revolution?Produced and presented by Sam FenwickIf you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukBusiness Daily is the home of in-depth audio journalism devoted to the world of money and work. From small start-up stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs. These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Photo: A man gets his waist measured. Credit: Getty Images)

Send a textEpisode Summary (Short Version):This week on On The Pen, Dave breaks down the rapid changes reshaping GLP-1 access — from new federal reforms targeting PBMs and possible FDA limits on compounded semaglutide, to Walgreens and Amazon launching cash-pay weight loss clinics.As insurance denials continue and out-of-pocket costs rise, patients are stuck between a shifting policy landscape and a growing direct-to-consumer market. Plus, an AI-designed oral GLP-1 enters Phase 3 trials, signaling how fast obesity medicine is evolving.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Canty recaps the sports weekend in Upon Further Review, which includes a potential trade at #1 overall. Why should we believe Jerry Jones is going to be a big spender this offseason? Michelle has a BIG issue with one NFL team's logo and thinks it's the reason they stink. I'm Over It: Canty was going to pile drive someone at a charity basketball game. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Canty recaps the sports weekend in Upon Further Review, which includes a potential trade at #1 overall. Why should we believe Jerry Jones is going to be a big spender this offseason? Michelle has a BIG issue with one NFL team's logo and thinks it's the reason they stink. I'm Over It: Canty was going to pile drive someone at a charity basketball game. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, Caroline hosts renowned plastic surgeon and star of Botched, Dr. Terry Dubrow, for a “hard questions” episode and some laughs. He educates us on Ozempic/GLP-1 drugs, microdosing, and newer peptide options like tirzepatide and the not-yet–FDA-approved “retatrutide,” which he says may help lower inflammation and support “preservation longevity” while AI accelerates disease breakthroughs. They discuss fears around AI, his belief that people should learn to use it, and his warning about unregulated online/black-market compounds. In beauty, Dubrow urges women to dial back fillers, avoid “Ozempic face panic,” be cautious with deep plane facelifts, and invest more in consistent energy devices (lasers/ultrasound/radiofrequency) rather than extreme procedures. He shares lessons from Botched and Plastic Surgery Rewind, including turning down risky patients, a memorable case removing “concrete” facial injections by reducing—not fully removing—masses, and how he and his wife test wellness trends on their “Doctor and Mrs. Guinea Pig” channel. He also covers peptides uncertainty, cycling use if someone insists, creatine findings, daily visualization, and marriage rules for handling conflict.Find Dr Dubrow - Website: www.drdubrow.com- Instagram: @drdubrow- TikTok: @drterrydubrow- Botched Presents: Plastic Surgery Rewind on E! and PeacockFollow Caroline:- Podcast: https://being-caroline.com/podcast/- IG: https://www.instagram.com/shop.with.caroline/- TikTok: https://www.tiktok.com/@shop.with.caroline- Facebook: https://www.facebook.com/beingcaroline- Search Looks: https://www.shop-with-caroline.com/- Shop New Merch: https://shop.dearmedia.com/collections/coming-in-hotPlease note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Sponsors:Text HOT to 64000 to get twenty percent off all IQBAR products, plus FREE shipping. Message and data rates may apply.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Zepbound and Mounjaro are reshaping the treatment of obesity — and transforming the global pharmaceutical market.Originally developed to treat type-2 diabetes, these injectable medicines — including semaglutide and tirzepatide — are now widely prescribed for weight loss, with growing evidence they can also reduce the risk of heart disease and stroke.But in the United States, access to GLP-1 drugs often depends on insurance coverage — and on who can afford to pay.In this first episode of a three-part Business Daily series on the global weight-loss economy, Sam Fenwick examines the real cost of obesity drugs in the U.S. healthcare system.How much do GLP-1 medications like Ozempic, Wegovy, Zepbound and Mounjaro actually cost? Are they cost-effective in the long term? And can insurers and employers afford to provide them to millions of Americans living with obesity?If you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukProduced and presented by Sam Fenwick.Business Daily is the home of in-depth audio journalism devoted to the world of money and work. From small startup stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the weight-loss drug revolution, the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs.These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Picture: Person standing on weighing scales. Credit: Press Association)

Canty recaps the sports weekend in Upon Further Review, which includes a potential trade at #1 overall. Why should we believe Jerry Jones is going to be a big spender this offseason? Michelle has a BIG issue with one NFL team's logo and thinks it's the reason they stink. I'm Over It: Canty was going to pile drive someone at a charity basketball game. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Canty recaps the sports weekend in Upon Further Review, which includes a potential trade at #1 overall. Why should we believe Jerry Jones is going to be a big spender this offseason? Michelle has a BIG issue with one NFL team's logo and thinks it's the reason they stink. I'm Over It: Canty was going to pile drive someone at a charity basketball game. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome back to our weekend Cabral HouseCall shows!   This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track!   Check out today's questions:    Sheena: Hi Dr. C! Hope you and your team are well. I was wondering what it means to rarely get sick. I'm 45 years old and can count on one hand how many times I've been sick the last 25+ years. Do I just have a really strong immune system or is something wrong? Is this normal? Isn't it good to get sick once or twice a year to build immunity? I keep thinking that when I DO get sick in the future as a senior, it'll be really bad from all the years of 'build up' lol looking forward to hearing your response! Thx!      Sarah: Hello, I have been struggling for several years with significant gastrointestinal symptoms, including alternating constipation and diarrhea, as well as painful bloating. I usually wake up with a flat stomach but by the end of the day I look 9 months pregnant. I was recently tested and found to be positive for both H. pylori and candida overgrowth. In your experience, which condition should be addressed first, and are there specific supplements or treatment protocols you typically recommend to begin care? Thank you so much!      Angela: Good evening, I have just stopped taking Ozempic because I have been having nausea and upper stomach pain for 5 months now. Went to doctor and found out I'm plugged up so the gave me some stuff to clear me out. It has helped my sugar a lot back to normal range and also my liver count is back to normal. I have lost 30 lbs which was to much but don't want all of it to come back. Just reaching out to see if there is something else I can do. Thanks Angela      Dave: Dr. Cabral, can you please explain the use of sunfiber or PHGG and if it is suitable for sensitive/irritable colon? Does it really help with butyrate producing bacteria? I would also like to ask about red and infrared devices targeting thyroid gland when there is autoimmunity, normal function, high antibodies and slight structural gland damage. Would you recommend red/infrared light device directly applied on the thyroid as a part of the destress thyroid specific protocol? If so, how long, how often, intermitently? Thank you for your advice.      Jenny: Hi Dr. Cabral - I have completed several lab tests and appreciate the coaching call that comes with them to review. When I've talked about this process with friends, some are skeptic regarding the blood spot card. How can I explain to them how the dried blood spots can be used to test some of the things traditional blood draws test with the same accuracy? Thank you!      Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/3676 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!